Carmel Pharma Introduces the Next Evolution of PhaSeal

Philadelphia, PA, May 16, 2008 --(PR.com)-- Carmel Pharma, Inc. will introduce the new Injector N35 with ErgoMotion™ at the 33rd ONS Annual Congress in Philadelphia, PA.

This new component employs the innovative and unique technology of ErgoMotion™ - a simple turn-key motion that provides easy access during hazardous drug preparation and administration - and is exclusive to the PhaSeal® System. Additional benefits include the same dry, leakproof connections that you’ve come to trust with PhaSeal, a single-handed grip and built-in locking mechanism.

Visit Carmel Pharma’s booth #532 to experience ErgoMotion™ and register to win a Nintendo™ Wii® console.

As the Gold Standard in Safe Handling for over 14 years, they continue to offer superior quality and innovative ways to make your job safer as well as easier. With over 14 peer-reviewed, independent studies currently available, PhaSeal is the only clinically proven closed-system drug transfer device available today. The System consists of an airtight Expansion Chamber that captures aerosols and vapors while equalizing the pressure in the vial, a Double membrane that ensures dry, leakproof connections, and a Needle-Safe Design that enables the retrieval of all the drug from the vial.

The PhaSeal System is manufactured in Gothenburg, Sweden and is distributed from its U.S. affiliate office in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and has been implemented in over 500 cancer centers, oncology practices, specialty pharmacies in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF. If you have questions regarding the PhaSeal System or Carmel Pharma, Inc., please contact Christine Crooks, Director of Marketing at 1-866-487-9250 ext.202, or online at www.phaseal.com.

###